Suppr超能文献

相似文献

1
A mixed methods study of provider factors in buprenorphine treatment retention.
Int J Drug Policy. 2022 Jul;105:103715. doi: 10.1016/j.drugpo.2022.103715. Epub 2022 May 6.
3
The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Health Serv Res. 2020 Jun;55(3):383-392. doi: 10.1111/1475-6773.13282. Epub 2020 Mar 12.
4
Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
J Subst Abuse Treat. 2022 Oct;141:108848. doi: 10.1016/j.jsat.2022.108848. Epub 2022 Jul 29.
5
Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study.
J Subst Use Addict Treat. 2023 Apr;147:208981. doi: 10.1016/j.josat.2023.208981. Epub 2023 Feb 10.
6
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
J Subst Abuse Treat. 2022 May;136:108686. doi: 10.1016/j.jsat.2021.108686. Epub 2021 Dec 15.
9
Buprenorphine prescribing practice trends and attitudes among New York providers.
J Subst Abuse Treat. 2017 Mar;74:1-6. doi: 10.1016/j.jsat.2016.10.005. Epub 2016 Oct 29.
10
Long-term retention in Office Based Opioid Treatment with buprenorphine.
J Subst Abuse Treat. 2017 Mar;74:65-70. doi: 10.1016/j.jsat.2016.12.010. Epub 2016 Dec 30.

引用本文的文献

1
Medicaid Unwinding and Changes in Buprenorphine Dispensing.
JAMA Netw Open. 2025 May 1;8(5):e258469. doi: 10.1001/jamanetworkopen.2025.8469.
3
Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.
Drug Alcohol Depend. 2025 Mar 1;268:112586. doi: 10.1016/j.drugalcdep.2025.112586. Epub 2025 Jan 29.
7
Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.
AIDS Behav. 2024 Dec;28(12):3994-4004. doi: 10.1007/s10461-024-04494-w. Epub 2024 Sep 12.
8
Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.
Drug Alcohol Depend. 2024 Oct 1;263:112389. doi: 10.1016/j.drugalcdep.2024.112389. Epub 2024 Aug 13.
9
State-level racial and ethnic disparities in buprenorphine treatment duration in the United States.
Am J Addict. 2025 Jan;34(1):69-74. doi: 10.1111/ajad.13638. Epub 2024 Aug 6.
10
Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.
Addict Sci Clin Pract. 2024 Mar 16;19(1):17. doi: 10.1186/s13722-024-00450-0.

本文引用的文献

2
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Subst Use Misuse. 2021;56(14):2181-2201. doi: 10.1080/10826084.2021.1975749. Epub 2021 Sep 20.
3
Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
Health Aff (Millwood). 2021 Jun;40(6):920-927. doi: 10.1377/hlthaff.2020.02261.
4
Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017.
Drug Alcohol Depend. 2021 Jun 1;223:108710. doi: 10.1016/j.drugalcdep.2021.108710. Epub 2021 Apr 20.
5
Achieving Mental Health Equity: Addictions.
Psychiatr Clin North Am. 2020 Sep;43(3):487-500. doi: 10.1016/j.psc.2020.05.007.
6
Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.
Health Aff (Millwood). 2020 Aug;39(8):1395-1404. doi: 10.1377/hlthaff.2019.01559.
7
Structural Racism and the Opioid Overdose Epidemic: The Need for Antiracist Public Health Practice.
J Public Health Manag Pract. 2020 May/Jun;26(3):201-205. doi: 10.1097/PHH.0000000000001168.
9
Defining Low-threshold Buprenorphine Treatment.
J Addict Med. 2020 Mar/Apr;14(2):95-98. doi: 10.1097/ADM.0000000000000555.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验